Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Predictive value of ABCB1 polymorphisms on sunitinib clearance and dose adjustment in cancer
2008-005438-57Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST), sponsored by Amsterdam University Medical Center. Primary endpoints: Correlation of ABCB1 polymorphisms with sunitinib clearance at steady state and Correlation of ABCB1 genotype with toxicity-adjusted sunitinib dose. Started Sep 2008; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on 2008-005438-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005438-57.